Results of a recent study shed light on observational and genetic associations between obesity and multiple female reproductive disorders, including uterine fibroids, PCOS, and heavy menstrual bleeding.
A pair of studies provide insight into the increased risk of dysglycemia among women with PCOS and the potential influence of combined oral contraceptive pills on this risk in a population-based cohort.
Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.
A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.
A meta-analysis of nearly a dozen studies presented at ENDO 2021 suggests Black women with PCOS were at an increased cardiometabolic risk, despite having comparable fasting glucose and lower triglyceride levels.